A5090905966- Antifungal resistance and susceptibility
- Transplantation: Methods and Outcomes
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Mycobacterium research and diagnosis
- Respiratory viral infections research
- Herpesvirus Infections and Treatments
- Nail Diseases and Treatments
- Immune Cell Function and Interaction
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Plant Pathogens and Fungal Diseases
- Organ Transplantation Techniques and Outcomes
- Pneumonia and Respiratory Infections
- Neutropenia and Cancer Infections
- Antibiotics Pharmacokinetics and Efficacy
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Tracheal and airway disorders
- Antibiotic Use and Resistance
- Infectious Diseases and Mycology
- Viral-associated cancers and disorders
- Nosocomial Infections in ICU
University Health Network
2016-2025
University of Toronto
2016-2025
Toronto General Hospital
2015-2025
Sinai Health System
2021-2024
Saudi Electronic University
2024
International Society for Heart and Lung Transplantation
2023
Advanced Circulatory System (United States)
2023
Aligarh Muslim University
2022-2023
Kumaun University
2023
Vancouver Infectious Diseases Centre
2023
Unique characteristics, impact of therapy with antifungal agents, and outcome infections Scedosporium species were assessed in transplant recipients.The patients comprised a total 80 recipients infections, including 13 from our institutions (University Pittsburgh Medical Center [Pittsburgh, PA], University Maryland [Baltimore], Duke [Durham, NC], Emory [Atlanta, GA], Hospital Gregorio Maranon [Madrid, Spain]) 67 reported the literature. The compared 190 non-transplant scedosporiosis who...
Risk factors for Nocardia infection in organ transplant recipients have not been formally assessed the current era of transplantation. We performed a matched case-control study (1:2 ratio) between January 1995 and December 2005. Control subjects were type timing. Univariate odds ratios determined conditional logistic regression was to identify independent risk factors. Clinical microbiological characteristics all case patients reviewed. Among 5126 recipients, 35 (0.6%) identified as having...
Background. The efficacy of the combination voriconazole and caspofungin when used as primary therapy for invasive aspergillosis in organ transplant recipients has not been defined. Methods. Transplant who received (n=40) (proven or probable) a prospective multicenter study between 2003 2005 were compared to control group comprising cohort consecutive 1999 2002 had lipid formulation AmB (n=47). In vitro antifungal testing Aspergillus isolates was correlated with clinical outcome. Results....
Background. Cytomegalovirus (CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest risk among donor CMV-seropositive, recipient-seronegative (D+/R−) patients. CMV-specific cell-mediated immunity may be able to predict which patients will develop CMV disease.
Abstract These updated AST‐IDCOP guidelines provide information on epidemiology, diagnosis, and management of Aspergillus after organ transplantation. is the most common invasive mold infection in solid‐organ transplant (SOT) recipients, it fungal among lung recipients. Time from to diagnosis aspergillosis (IA) variable, but cases present within first year post‐transplant, with shortest time onset liver heart The overall 12‐week mortality IA SOT exceeds 20%; prognosis worse those central...
To determine the spectrum and impact of mycelial fungal infections, particularly those due to non-Aspergillus molds, 53 liver heart transplant recipients with invasive infections were prospectively identified in a multicenter study. Invasive Aspergillus species 69.8% patients, hyalohyphomycetes 9.4%, phaeohyphomycetes zygomycetes 5.7%, other causes 5.7%. Infections fungi than significantly more likely be associated disseminated (P=.005) central nervous system (P=.07) infection species....
Abstract Unique clinical characteristics and other variables influencing the outcome of Cryptococcus neoformans infection in organ transplant recipients have not been well defined. From a review published reports, we found that C. was documented 2.8% (overall death rate 42%). The type primary immunosuppressive agent used transplantation influenced predominant manifestation cryptococcosis. Patients receiving tacrolimus were significantly less likely to central nervous system involvement (78%...
Background. Alemtuzumab is being increasingly used for the prevention and/or treatment of acute allograft rejection in organ transplant recipients. We assessed risks infection in, to our knowledge, largest cohort and broadest range recipients yet reported have received alemtuzumab. Methods. All patients who alemtuzumab from September 2002 through March 2004, either as induction therapy at time transplantation or rejection, were evaluated development an opportunistic (OI) until death 12...
Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring patients receiving other indications. The possible mechanisms of resistance and pharmacokinetic limitations drug are addressed. Methods: records involved were systematically reviewed. susceptibility testing was...
Variables influencing the risk of dissemination and outcome Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis a prospective, multicenter, international study. Sixty-one percent (68/111) patients had disseminated infection. The was significantly higher for liver (adjusted hazard ratio [HR], 6.65; P=.048). overall mortality rate at 90 days 14% (16/111). abnormal mental status (P=.023), renal failure baseline (P=.028), fungemia (P=.006),...
We describe an immune reconstitution syndrome (IRS)-like entity in the course of evolution Cryptococcus neoformans infection organ transplant recipients. The study population comprised a cohort 83 consecutive recipients with cryptococcosis who were observed for median 2 years international, multicenter study. In 4 (4.8%) patients, IRS-like was 5.5 weeks after initiation appropriate antifungal therapy. Worsening clinical manifestations documented, despite cultures being negative C....
To discern whether the characteristics and outcome of invasive aspergillosis in liver transplant recipients have evolved during past decade, 26 patients who underwent transplantation 1990-1995 (known as "the earlier cohort") were compared with 20 1998-2001 later cohort"). Twenty-three percent Aspergillus infections cohort occurred > or =90 days after transplantation, 55% such (P=.026). The was significantly more likely to disseminated infection (P=.034) central nervous system (CNS)...
Lung transplant recipients have one of the highest rates invasive aspergillosis (IA) in solid organ transplantation. We used a single center, nonrandomized, retrospective, sequential study design to evaluate fungal infection lung who were managed with either universal prophylaxis voriconazole (n = 65) or targeted 30) itraconazole +/- inhaled amphotericin patients at high risk (pre- posttransplant Aspergillus colonization [except niger]). The rate IA 1 year was better receiving as compared...
The clinical utility of Platelia trade mark Aspergillus galactomannan antigen for the early diagnosis invasive aspergillosis was prospectively assessed in 70 consecutive lung transplant recipients. Sera were collected twice weekly and tested galactomannan. Invasive documented 17.1% (12/70) patients. Using generalized estimating equation model, at cutoff value >or= 0.5, sensitivity test 30%, specificity 93% with positive negative likelihood ratios 4.2 0.75, respectively. Increasing to 0.66...
In the absence of standardized diagnosis and presence unique clinical syndromes, it is not surprising that considerable differences exist in number reported incidences disease outcomes various infections cardiothoracic transplant (CTTX) recipients. Publications to date have employed variable heterogeneous definitions CTTX-related infections, thereby limiting comparison between types incidence generalizability these data across centers. Currently, there are no standard international for...